161 related articles for article (PubMed ID: 34246575)
1. Pharmacist furnishing of naloxone in California: A follow-up analysis.
Puzantian T; Gasper JJ; Ramirez CM
J Am Pharm Assoc (2003); 2021; 61(5):e108-e112. PubMed ID: 34246575
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of naloxone furnishing community pharmacies in San Francisco.
Nguyen AM; Kearney TE; Apollonio DE
J Am Pharm Assoc (2003); 2020; 60(6):1050-1057.e1. PubMed ID: 32948461
[TBL] [Abstract][Full Text] [Related]
3. An observational study of the extent of naloxone furnishing in California Central Valley community pharmacies.
Banawis M; Mah G; Mohsin R; Pobre J; Tracy D; Song AV; Apollonio DE
J Am Pharm Assoc (2003); 2023; 63(2):566-573. PubMed ID: 36476261
[TBL] [Abstract][Full Text] [Related]
4. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
[TBL] [Abstract][Full Text] [Related]
5. Naloxone availability in independent community pharmacies in Georgia, 2019.
Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
[TBL] [Abstract][Full Text] [Related]
6. Impact of pharmacist counseling to enhance the accessibility of naloxone nasal spray to patients in a community pharmacy setting.
Napoli K; Grant M; Remines J; Nadpara P; Goode JR
J Am Pharm Assoc (2003); 2021; 61(4S):S127-S134. PubMed ID: 33441280
[TBL] [Abstract][Full Text] [Related]
7. Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia.
Karthikeyan N; Xia T; Nielsen S; Picco L
Drug Alcohol Rev; 2024 Jul; 43(5):1305-1312. PubMed ID: 38691509
[TBL] [Abstract][Full Text] [Related]
8. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
9. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
10. Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
Pollini RA; Joyce R; Ozga-Hess JE; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2020; 60(6):853-860. PubMed ID: 32651116
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with naloxone availability and dispensing through Michigan's pharmacy standing order.
Dahlem CH; Myers M; Goldstick J; Stevenson JG; Gray G; Rockhill S; Dora-Laskey A; Kellenberg J; Brummett CM; Kocher KE
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):454-463. PubMed ID: 35405078
[No Abstract] [Full Text] [Related]
12. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas.
Evoy KE; Groff L; Hill LG; Godinez W; Gandhi R; Reveles KR
J Am Pharm Assoc (2003); 2020; 60(1):81-86. PubMed ID: 31669417
[TBL] [Abstract][Full Text] [Related]
13. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
[TBL] [Abstract][Full Text] [Related]
14. Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.
Pollini RA; Ozga JE; Joyce R; Xuan Z; Walley AY
Drug Alcohol Depend; 2022 Feb; 231():109259. PubMed ID: 34998246
[TBL] [Abstract][Full Text] [Related]
15. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies.
Spivey CA; Wilder A; Chisholm-Burns MA; Stallworth S; Wheeler J
J Am Pharm Assoc (2003); 2020; 60(5):694-701.e1. PubMed ID: 32146134
[TBL] [Abstract][Full Text] [Related]
17. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
18. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
20. Availability and Cost of Naloxone Nasal Spray at Pharmacies in Philadelphia, Pennsylvania, 2017.
Guadamuz JS; Alexander GC; Chaudhri T; Trotzky-Sirr R; Qato DM
JAMA Netw Open; 2019 Jun; 2(6):e195388. PubMed ID: 31173125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]